




# Lexi-Comp® FORMULINK<sup>SM</sup>

## Superior Clinical Content and Hospital-Specific Information in One Hospital-Wide Resource!



### Lexi-Comp® ONLINE™

A Single Comprehensive Resource providing your entire clinical staff with:

- AHFS® & Lexi-Comp Drug Information
- Drug Interaction Analysis
- Disease and Diagnostic Management
- Adult & Pediatric Education Leaflets
- Lab Test & Diagnostic Procedures
- Natural Products
- Drug Identification
- Toxicology
- Calculations

FORMULINK, Lexi-Comp's electronic formulary service, integrates an institution's formulary, policies and procedures, and therapeutic guidelines with Lexi-Comp's trusted clinical content. A single search provides review of formulary drug status and quick access to current clinical information within our hospital-wide, Internet-based platform.

### Features & Benefits:

- Full integration within Lexi-Comp® ONLINE™, eliminating the need for multiple resources
- Continually-updated content and Special Alerts
- Reduce medication costs through formulary compliance
- Tools to easily update your formulary after P&T meetings
- Comply with Joint Commission Requirements
- Customizable features and web links to hospital policies and procedures
- Unlimited PDA formulary downloads with purchase of Lexi-Comp® ON-HAND™ option

We provide the tools for hospitals and health systems to manage and seamlessly communicate hospital-specific formulary information throughout an institution. Use our online editing software to update your formulary or allow our formulary managers to update for you.

To learn more about Lexi-Comp FORMULINK, visit [www.lexi.com/institutions/products/formulary](http://www.lexi.com/institutions/products/formulary)



Please see reverse for illustrated benefits of Lexi-Comp FORMULINK.





## Illustration of a customized Lexi-Comp® ONLINE™ hospital formulary interface

This screenshot shows the Lexi-Comp ONLINE search results for 'lipitor'. The search bar at the top left contains 'lipitor' and 'Within: Name'. Below the search bar are navigation tabs: HOME, INDEXES, SEARCH, Interactions, Drug ID, Calculations, I.V. Compatibility, Patient Education, Web Search, Drug Plans, Toxicology, and Logout. The search results are categorized into 'Hospital Formulary (Example Database)', 'Lexi-Comp ONLINE', 'Pediatric Lexi-Drugs Online', 'AHFS Essentials (Adult and Pediatric)', 'AHFS DI (Adult and Pediatric)', 'Generic Lexi-Drugs Online', and 'Pharmacogenomics Online'. A red box highlights the 'Hospital Formulary (Example Database)' section, which lists 'Lipitor® U.S. brand name for Atorvastatin Calcium Updated 01/16/09'.

When performing a search in Lexi-Comp ONLINE, your institution's formulary information will appear first in the search results window. This allows your staff to easily access hospital-specific information.

This screenshot shows the detailed view of the 'Atorvastatin' hospital formulary entry. The search bar at the top left contains 'lipitor' and 'Within: Name'. Below the search bar are navigation tabs: HOME, INDEXES, SEARCH, Interactions, Drug ID, Calculations, I.V. Compatibility, Patient Education, Web Search, Drug Plans, Toxicology, and Logout. The main content area is titled 'Atorvastatin Hospital Formulary (Example Database)'. It includes a 'Special Alerts' section with a link to 'HMG-CoA Reductase Inhibitors: Evidence Does Not Suggest Increased Incidence of Amyotrophic Lateral Sclerosis (ALS) - Results of FDA Analysis - September 30, 2008'. A red box highlights the 'Special Alerts' section. The text below the alert states: 'The U.S. Food and Drug Administration's (FDA) review of 41 long-term controlled clinical trials of HMG-CoA reductase inhibitors finds no evidence of an increased incidence of ALS (also known as Lou Gehrig's disease) related to these medications. This analysis occurred after the FDA had received notice of numerous adverse events of which 109 of these reports mentioned ALS, Lou Gehrig's disease, or motor neurone disease. The clinical trials included in the analysis had a median duration of treatment of 3.3 years (range of duration: 6 months to 5 years) and involved 120,964 patients. The analysis identified a total of 19 cases of ALS - 9 cases per 64,602 patients (0.014%) with statin therapy and 10 cases per 56,362 patients (0.017%) with placebo. The incidence rates, based on approximately 400,000 person-years, were 4.2 per 100,000 person-years in the statin-treated group and 5 per 100,000 person-years in the placebo-treated group. The FDA recommends that health care providers continue to prescribe, and patients continue to'.

Once within your hospital formulary, your staff can view fields of information specific to your institution and shared fields from Lexi-Comp's information.

This screenshot shows the detailed view of the 'Atorvastatin' hospital formulary entry, focusing on the 'Special Alerts' section. The search bar at the top left contains 'lipitor' and 'Within: Name'. Below the search bar are navigation tabs: HOME, INDEXES, SEARCH, Interactions, Drug ID, Calculations, I.V. Compatibility, Patient Education, Web Search, Drug Plans, Toxicology, and Logout. The main content area is titled 'Atorvastatin Hospital Formulary (Example Database)'. It includes a 'Special Alerts' section with a link to 'HMG-CoA Reductase Inhibitors: Evidence Does Not Suggest Increased Incidence of Amyotrophic Lateral Sclerosis (ALS) - Results of FDA Analysis - September 30, 2008'. A red box highlights the 'Special Alerts' section. The text below the alert states: 'The U.S. Food and Drug Administration's (FDA) review of 41 long-term controlled clinical trials of HMG-CoA reductase inhibitors finds no evidence of an increased incidence of ALS (also known as Lou Gehrig's disease) related to these medications. This analysis occurred after the FDA had received notice of numerous adverse events of which 109 of these reports mentioned ALS, Lou Gehrig's disease, or motor neurone disease. The clinical trials included in the analysis had a median duration of treatment of 3.3 years (range of duration: 6 months to 5 years) and involved 120,964 patients. The analysis identified a total of 19 cases of ALS - 9 cases per 64,602 patients (0.014%) with statin therapy and 10 cases per 56,362 patients (0.017%) with placebo. The incidence rates, based on approximately 400,000 person-years, were 4.2 per 100,000 person-years in the statin-treated group and 5 per 100,000 person-years in the placebo-treated group. The FDA recommends that health care providers continue to prescribe, and patients continue to'. Below the alert, there are sections for 'Comments', 'Medication Safety Issues', 'Web Links', 'U.S. Brand Names', 'Therapeutic Category', and 'Dosage Forms'. A red box highlights the 'Web Links' section, which includes a link to 'National Guideline Clearinghouse'.

Utilize web links to direct your staff to hospital guidelines or other information that is located on your hospital intranet.

Philippine Distributor:



Room 301 Auro-Vir Plaza, Evangelista St., Makati City 1233  
Tel Nos 63 2 8436571/ 8453507 Fax 63 2 3250027  
Mobile 63 922 8829759 Email: eisi@eisi.com.ph